tradingkey.logo

Nuvation Bio Inc <NUVB.N> expected to post a loss of 16 cents a share - Earnings Preview

ReutersMay 5, 2025 11:10 PM
  • Nuvation Bio Inc NUVB.N, NUVB.K is expected to show a rise in quarterly revenue when it reports results on May 7 for the period ending March 31 2025

  • The San Francisco California-based company is expected to report revenue of $416.67 thousand, according to the mean estimate from 6 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Nuvation Bio Inc is for a loss of 16 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Nuvation Bio Inc is $8.00​, above​ its last closing price of $2.38. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.14

-0.14

-0.15

Missed

-8.7

Sep. 30 2024

-0.12

-0.13

-0.15

Missed

-15.4

Jun. 30 2024

-0.06

-0.06

-0.15

Missed

-156.4​

Mar. 31 2024

-0.09

-0.10

-0.07

Beat

26.9

​​Dec. 31 2023

-0.09

-0.10

-0.06

Beat

42.8

Sep. 30 2023

-0.11

-0.11

-0.09

Beat

17.9​

Jun. 30 2023

-0.11

-0.11

-0.09

Beat

19.5

Mar. 31 2023

-0.10

-0.10

-0.10

Met

0

This summary was machine generated May 5 at 23:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI